JP2012180345A5 - - Google Patents

Download PDF

Info

Publication number
JP2012180345A5
JP2012180345A5 JP2012024721A JP2012024721A JP2012180345A5 JP 2012180345 A5 JP2012180345 A5 JP 2012180345A5 JP 2012024721 A JP2012024721 A JP 2012024721A JP 2012024721 A JP2012024721 A JP 2012024721A JP 2012180345 A5 JP2012180345 A5 JP 2012180345A5
Authority
JP
Japan
Prior art keywords
acid
hydroxide
mmol
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012024721A
Other languages
English (en)
Japanese (ja)
Other versions
JP5921235B2 (ja
JP2012180345A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012024721A priority Critical patent/JP5921235B2/ja
Priority claimed from JP2012024721A external-priority patent/JP5921235B2/ja
Publication of JP2012180345A publication Critical patent/JP2012180345A/ja
Publication of JP2012180345A5 publication Critical patent/JP2012180345A5/ja
Application granted granted Critical
Publication of JP5921235B2 publication Critical patent/JP5921235B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012024721A 2011-02-09 2012-02-08 3−ヒドロキシ−6H−ベンゾ[c]クロメン−6−オン誘導体およびその製造方法 Expired - Fee Related JP5921235B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012024721A JP5921235B2 (ja) 2011-02-09 2012-02-08 3−ヒドロキシ−6H−ベンゾ[c]クロメン−6−オン誘導体およびその製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011026188 2011-02-09
JP2011026188 2011-02-09
JP2012024721A JP5921235B2 (ja) 2011-02-09 2012-02-08 3−ヒドロキシ−6H−ベンゾ[c]クロメン−6−オン誘導体およびその製造方法

Publications (3)

Publication Number Publication Date
JP2012180345A JP2012180345A (ja) 2012-09-20
JP2012180345A5 true JP2012180345A5 (cg-RX-API-DMAC7.html) 2015-03-12
JP5921235B2 JP5921235B2 (ja) 2016-05-24

Family

ID=46638668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012024721A Expired - Fee Related JP5921235B2 (ja) 2011-02-09 2012-02-08 3−ヒドロキシ−6H−ベンゾ[c]クロメン−6−オン誘導体およびその製造方法

Country Status (8)

Country Link
US (2) US8802869B2 (cg-RX-API-DMAC7.html)
EP (1) EP2674422A4 (cg-RX-API-DMAC7.html)
JP (1) JP5921235B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140002735A (cg-RX-API-DMAC7.html)
CN (1) CN103370310A (cg-RX-API-DMAC7.html)
CA (1) CA2826871A1 (cg-RX-API-DMAC7.html)
TW (1) TW201309663A (cg-RX-API-DMAC7.html)
WO (1) WO2012108455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US9394269B2 (en) * 2013-12-23 2016-07-19 Amazentis Sa Process-scale synthesis of urolithins
WO2015154047A1 (en) * 2014-04-03 2015-10-08 Restorgenex Corporation Novel methods
CN105884739B (zh) * 2016-04-14 2018-04-27 广西大学 一种苯并香豆素多环化合物的合成方法
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
IL313537A (en) * 2018-02-27 2024-08-01 Amazentis Sa Urolitin A synthesis process
CN111039913A (zh) * 2018-10-15 2020-04-21 韦忠友 一种具有抗肿瘤作用的化合物的制备方法
CA3206062A1 (en) * 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
IL320449A (en) 2022-10-25 2025-06-01 Artus Therapeutics Inc Medical factors to improve epithelial and/or endothelial barrier function
CN119661547A (zh) * 2023-09-20 2025-03-21 科辉智药(深圳)新药研究中心有限公司 作为sarm1酶活性抑制剂的三环吡啶类化合物及其应用
CN117756766A (zh) * 2023-12-20 2024-03-26 常州大学 3-羟基-8-氟-6H-苯并[c]色烯-6-酮类衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073612A2 (en) * 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
US20050282781A1 (en) * 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
CN101263119B (zh) 2005-09-14 2014-04-09 参天制药株式会社 具有糖皮质激素受体结合活性的1,2-二氢喹啉衍生物
ES2391910T3 (es) 2006-11-14 2012-12-03 Santen Pharmaceutical Co., Ltd Derivado de 1,2-dihidroquinolina que tiene un grupo (fenil sustituido o heterociclil sustituido)carboniloxi-alquilo inferior y un grupo fenilo introducido por éster como sustituyentes
AU2009247250B2 (en) * 2008-05-12 2014-04-10 Ayumi Pharmaceutical Corporation Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group

Similar Documents

Publication Publication Date Title
JP2012180345A5 (cg-RX-API-DMAC7.html)
JP2005179362A5 (cg-RX-API-DMAC7.html)
CN102532116A (zh) 抗肿瘤靶向治疗药物tivozanib的合成方法
CN103880683B (zh) 一种3-溴-2-硝基苯甲醛的化学合成方法
JP2011507988A5 (cg-RX-API-DMAC7.html)
CN104829549A (zh) 5,5′-联四唑-1,1′-二氧金属盐及其合成方法
JP2014520848A5 (cg-RX-API-DMAC7.html)
CN103058899B (zh) 一种对甲砜基苯甲醛的合成方法
RU2017142996A (ru) Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма
JP2017111398A5 (cg-RX-API-DMAC7.html)
CN104072384A (zh) 一种美沙拉嗪的合成收率方法
JP5936511B2 (ja) 3,3’−ジニトロ−4,4’−ジヒドロキシジフェニルエーテルの精製方法および3,3’−ジニトロ−4,4’−ジヒドロキシジフェニルエーテルの製造方法
CN103709209A (zh) 异丙基-β-D-硫代半乳糖苷的制备方法
CN101402589A (zh) 一种2-溴-4-硝基苯乙腈的合成方法
CN103709210B (zh) 异丙基-β-D-硫代半乳糖苷的制备工艺
CN103694286B (zh) 制备异丙基-β-D-硫代半乳糖苷的方法
CN101921194A (zh) 一种制备4-氯二苯甲胺的方法
WO2018121050A1 (zh) 一种3-氰基-4-羟基苯甲酸甲酯的制备方法
CN111393376B (zh) 一种2-氯嘧啶-4-甲酸的合成方法
KR20180105450A (ko) 피마살탄 콜린염 및 이의 수화물의 제조방법
CN103333147B (zh) 7,4’-o-二苄基槲皮素的合成方法
CN104447428A (zh) 一种酚磺乙胺的制备方法
CN103694285B (zh) 一种异丙基-β-D-硫代半乳糖苷的制备方法
CN110357773A (zh) 3-氯-4-羟基苯甲酸的合成
RU2426723C1 (ru) Способ получения 2,3,5,6-тетрабром-4-нитрофенола